These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 10905493)

  • 21. Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with Type II diabetes.
    Ebeling P; Teppo AM; Koistinen HA; Viikari J; Rönnemaa T; Nissén M; Bergkulla S; Salmela P; Saltevo J; Koivisto VA
    Diabetologia; 1999 Dec; 42(12):1433-8. PubMed ID: 10651262
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute non-insulin-like stimulation of rat muscle glucose metabolism by troglitazone in vitro.
    Fürnsinn C; Neschen S; Noe C; Bisschop M; Roden M; Vogl C; Schneider B; Waldhäusl W
    Br J Pharmacol; 1997 Dec; 122(7):1367-74. PubMed ID: 9421284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Troglitazone treatment increases protein kinase B phosphorylation in skeletal muscle of normoglycemic subjects at risk for the development of type 2 diabetes.
    Meyer MM; Levin K; Grimmsmann T; Perwitz N; Eirich A; Beck-Nielsen H; Klein HH
    Diabetes; 2002 Sep; 51(9):2691-7. PubMed ID: 12196460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Troglitazone directly inhibits CO(2) production from glucose and palmitate in isolated rat skeletal muscle.
    Fürnsinn C; Brunmair B; Neschen S; Roden M; Waldhäusl W
    J Pharmacol Exp Ther; 2000 May; 293(2):487-93. PubMed ID: 10773019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Troglitazone: a review of its use in the management of type 2 diabetes mellitus.
    Plosker GL; Faulds D
    Drugs; 1999 Mar; 57(3):409-38. PubMed ID: 10193691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Troglitazone prevents hyperglycemia-induced but not glucosamine-induced insulin resistance.
    Miles PD; Higo K; Romeo OM; Lee MK; Rafaat K; Olefsky JM
    Diabetes; 1998 Mar; 47(3):395-400. PubMed ID: 9519745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of troglitazone on cellular differentiation, insulin signaling, and glucose metabolism in cultured human skeletal muscle cells.
    Kausch C; Krützfeldt J; Witke A; Rettig A; Bachmann O; Rett K; Matthaei S; Machicao F; Häring HU; Stumvoll M
    Biochem Biophys Res Commun; 2001 Jan; 280(3):664-74. PubMed ID: 11162573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
    Nolan JJ; Ludvik B; Beerdsen P; Joyce M; Olefsky J
    N Engl J Med; 1994 Nov; 331(18):1188-93. PubMed ID: 7935656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus.
    Johnson MD; Campbell LK; Campbell RK
    Ann Pharmacother; 1998 Mar; 32(3):337-48. PubMed ID: 9533065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus.
    Prigeon RL; Kahn SE; Porte D
    J Clin Endocrinol Metab; 1998 Mar; 83(3):819-23. PubMed ID: 9506734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanism of impaired insulin-stimulated muscle glucose metabolism in subjects with insulin-dependent diabetes mellitus.
    Cline GW; Magnusson I; Rothman DL; Petersen KF; Laurent D; Shulman GI
    J Clin Invest; 1997 May; 99(9):2219-24. PubMed ID: 9151794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of troglitazone on substrate storage and utilization in insulin-resistant rats.
    Sreenan S; Keck S; Fuller T; Cockburn B; Burant CF
    Am J Physiol; 1999 Jun; 276(6):E1119-29. PubMed ID: 10362626
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy.
    Phillips SA; Ciaraldi TP; Kong AP; Bandukwala R; Aroda V; Carter L; Baxi S; Mudaliar SR; Henry RR
    Diabetes; 2003 Mar; 52(3):667-74. PubMed ID: 12606507
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic control analysis of insulin-stimulated glucose disposal in rat skeletal muscle.
    Jucker BM; Barucci N; Shulman GI
    Am J Physiol; 1999 Sep; 277(3):E505-12. PubMed ID: 10484363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Troglitazone antagonizes metabolic effects of glucocorticoids in humans: effects on glucose tolerance, insulin sensitivity, suppression of free fatty acids, and leptin.
    Willi SM; Kennedy A; Wallace P; Ganaway E; Rogers NL; Garvey WT
    Diabetes; 2002 Oct; 51(10):2895-902. PubMed ID: 12351424
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM.
    Berkowitz K; Peters R; Kjos SL; Goico J; Marroquin A; Dunn ME; Xiang A; Azen S; Buchanan TA
    Diabetes; 1996 Nov; 45(11):1572-9. PubMed ID: 8866563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cellular mechanisms of insulin resistance in humans.
    Shulman GI
    Am J Cardiol; 1999 Jul; 84(1A):3J-10J. PubMed ID: 10418851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes.
    Buchanan TA; Xiang AH; Peters RK; Kjos SL; Berkowitz K; Marroquin A; Goico J; Ochoa C; Azen SP
    Diabetes; 2000 May; 49(5):782-8. PubMed ID: 10905487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone.
    Iwamoto Y; Kosaka K; Kuzuya T; Akanuma Y; Shigeta Y; Kaneko T
    Diabet Med; 1996 Apr; 13(4):365-70. PubMed ID: 9162613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic effects of Troglitazone in patients with diet-controlled type 2 diabetes.
    Robinson AC; Jeffs JA; Gray RG; Bannister PA; Mather H; Gallagher JJ; Robinson S; Nattrass M; Venkatesan S; Halliday D; Johnston DG
    Eur J Clin Invest; 2004 Jan; 34(1):29-36. PubMed ID: 14984435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.